Targeted Next-Generation Sequencing-Based Mutational Signature Analysis in Hypermutated Gliomas: A Case-Centered Feasibility Assessment.

IF 1.7 4区 医学 Q3 CELL BIOLOGY
Pathobiology Pub Date : 2026-07-07 DOI:10.1159/000553407
Seon Ung Kim, Youn Soo Lee, Sin-Soo Jeun, Jae-Sung Park, Donghyuk Lee, Jun Kang
{"title":"Targeted Next-Generation Sequencing-Based Mutational Signature Analysis in Hypermutated Gliomas: A Case-Centered Feasibility Assessment.","authors":"Seon Ung Kim, Youn Soo Lee, Sin-Soo Jeun, Jae-Sung Park, Donghyuk Lee, Jun Kang","doi":"10.1159/000553407","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Gliomas generally display a low tumor mutational burden (TMB) and an immunosuppressive microenvironment, both of which restrict the effectiveness of immune checkpoint inhibitors. However, certain gliomas acquire a high TMB, which may arise either due to temozolomide (TMZ) therapy or mismatch repair deficiency. Mutational signature analysis identifies specific somatic mutation patterns, providing insight into underlying mutational mechanisms. This study provides a case-centered feasibility assessment of mutational signature refitting from a clinically implemented targeted next-generation sequencing (NGS) panel in two hypermutated gliomas identified within a real-world glioma testing cohort.</p><p><strong>Methods: </strong>Twenty-eight gliomas tested using the Oncomine Comprehensive Assay Plus NGS panel in routine clinical practice were retrospectively reviewed. Panel-derived TMB was used for coarse stratification and to identify hypermutated tumors for detailed mutational signature interpretation. Mutational signature refitting was performed using Signature Analyzer for Targeted Sequencing.</p><p><strong>Results: </strong>Two gliomas exhibited elevated panel-derived TMB estimates: one after TMZ therapy and another in association with MSH2 deficiency. The remaining 26 non-hypermutated tumors had sparse mutation counts, limiting reliable signature interpretation. COSMIC single-base substitution signature 11 (SBS11) was predominant in the TMZ-treated hypermutated glioma, whereas the MSH2-deficient glioma demonstrated increased SBS1 and SBS26.</p><p><strong>Conclusion: </strong>This real-world, case-centered study suggests that targeted-panel mutational signature refitting may provide complementary molecular context in selected hypermutated gliomas. The observed patterns were concordant with prior TMZ exposure or mismatch repair deficiency. However, in non-hypermutated tumors, sparse mutation counts limited reliable signature interpretation, and the clinical impact of this approach remains to be established.</p>","PeriodicalId":19805,"journal":{"name":"Pathobiology","volume":" ","pages":"1-10"},"PeriodicalIF":1.7000,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000553407","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Gliomas generally display a low tumor mutational burden (TMB) and an immunosuppressive microenvironment, both of which restrict the effectiveness of immune checkpoint inhibitors. However, certain gliomas acquire a high TMB, which may arise either due to temozolomide (TMZ) therapy or mismatch repair deficiency. Mutational signature analysis identifies specific somatic mutation patterns, providing insight into underlying mutational mechanisms. This study provides a case-centered feasibility assessment of mutational signature refitting from a clinically implemented targeted next-generation sequencing (NGS) panel in two hypermutated gliomas identified within a real-world glioma testing cohort.

Methods: Twenty-eight gliomas tested using the Oncomine Comprehensive Assay Plus NGS panel in routine clinical practice were retrospectively reviewed. Panel-derived TMB was used for coarse stratification and to identify hypermutated tumors for detailed mutational signature interpretation. Mutational signature refitting was performed using Signature Analyzer for Targeted Sequencing.

Results: Two gliomas exhibited elevated panel-derived TMB estimates: one after TMZ therapy and another in association with MSH2 deficiency. The remaining 26 non-hypermutated tumors had sparse mutation counts, limiting reliable signature interpretation. COSMIC single-base substitution signature 11 (SBS11) was predominant in the TMZ-treated hypermutated glioma, whereas the MSH2-deficient glioma demonstrated increased SBS1 and SBS26.

Conclusion: This real-world, case-centered study suggests that targeted-panel mutational signature refitting may provide complementary molecular context in selected hypermutated gliomas. The observed patterns were concordant with prior TMZ exposure or mismatch repair deficiency. However, in non-hypermutated tumors, sparse mutation counts limited reliable signature interpretation, and the clinical impact of this approach remains to be established.

靶向基于ngs的突变特征分析在高突变胶质瘤:以病例为中心的可行性评估。
胶质瘤通常表现为低肿瘤突变负荷(TMB)和免疫抑制微环境,这两者都限制了免疫检查点抑制剂的有效性。然而,某些胶质瘤获得高TMB,这可能是由于替莫唑胺(TMZ)治疗或错配修复缺陷(MMRd)引起的。突变特征分析识别特定的体细胞突变模式,提供对潜在突变机制的洞察。本研究提供了一个以病例为中心的可行性评估,从临床实施的靶向NGS面板中,在现实世界的胶质瘤测试队列中鉴定出两个超突变胶质瘤。方法:回顾性分析在常规临床实践中使用Oncomine综合检测加NGS面板检测的28例胶质瘤。小组衍生的TMB用于粗分层和识别高突变肿瘤,以进行详细的突变特征解释。使用靶向测序特征分析仪(SATS)进行突变特征修正。结果:两个胶质瘤表现出升高的组源性TMB估计:一个在TMZ治疗后,另一个与MSH2缺乏有关。其余26个非超突变肿瘤的突变计数稀疏,限制了可靠的特征解释。COSMIC单碱基取代特征11 (SBS11)在tmz治疗的高突变胶质瘤中占主导地位,而msh2缺陷胶质瘤则表现出SBS1和SBS26的增加。结论:这项现实世界的以病例为中心的研究表明,靶向面板突变特征修饰可能为选定的高突变胶质瘤提供补充的分子背景。观察到的模式与先前的TMZ暴露或错配修复缺陷一致。然而,在非高突变的肿瘤中,稀疏的突变计数限制了可靠的特征解释,这种方法的临床影响仍有待确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathobiology
Pathobiology 医学-病理学
CiteScore
8.50
自引率
0.00%
发文量
47
审稿时长
>12 weeks
期刊介绍: ''Pathobiology'' offers a valuable platform for the publication of high-quality original research into the mechanisms underlying human disease. Aiming to serve as a bridge between basic biomedical research and clinical medicine, the journal welcomes articles from scientific areas such as pathology, oncology, anatomy, virology, internal medicine, surgery, cell and molecular biology, and immunology. Published bimonthly, ''Pathobiology'' features original research papers and reviews on translational research. The journal offers the possibility to publish proceedings of meetings dedicated to one particular topic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书